Blue Chip Stock SinoPharm HKG:1099 The company distributes medicine to hospitals, pharmacies, and clinics. They also run pharmacy stores, distribute medical devices and laboratory supplies, make chemical reagents, and sell […]
Blue Chip Stock Sino Biopharm HKG:1177 Updated: September 15, 2024 Ex Dividend: N/A Quick glance, Price-to-earnings (P/E ratio): 25.17 Price-to-Book ratio : 1.53 preferably <1 although some value investors like […]
Blue Chip Stock CSPC Pharma HKG:1093 August 2020 the first Interim Dividend was announced. For CSPC Pharma Dividend Growth and Safety look promising, but is this a dividend stock that […]
Blue Chip Stock Hansoh Pharma HKG:3692 0 Updated: September 15, 2024 Ex Dividend: 20-Sep Quick glance, Price-to-earnings (P/E ratio): 19.35 Price-to-Book ratio : 3.22 preferably <1 although some value investors […]
HKG:3613 Tong Ren Tang 1H 2022 a special dividend was announced. Final dividend got a raise of 17%. This company is heading to become dividend contender next year. And let’s not forget the beautiful dividend chart. The special dividends is left out conveniently.
HKG:1099 SINOPHARM Dividend is in RMB also here. Other than that, things look nice. Not too splendid on the yield side , but consistent growth in dividend. So sit and wait till the time is right.
HKG:1681 Consun Pharm The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
HKG:1177 Sino Biopharm The Group’s business works in a fully integrated chain which spans from R&D to manufacture and sales of pharmaceutical products, covering a vast array of biopharmaceutical, chemical and modernized Chinese medicines. Interim result 2022 are favorable for dividends (+200%) yet EPS fell 77%
HKG:0867 CMS What a beautiful chart! Results of 2022 are okay. Dividends got up 2.5% , Debt/Equity remained stable. This looks promising in terms of higher proceeds of holding this stock. (Average 5-yr Dividend Growth is almost 15%)
